MorphoSys AG Expands Japanese Alliance With GeneFrontier Corporation
Published: Jan 25, 2007
MARTINSRIED, Germany, Jan. 25, 2007 (PRIME NEWSWIRE) (PRIMEZONE) -- MorphoSys AG (Frankfurt:MOR) today announced an expansion of its existing marketing alliance with its Tokyo-based partner GeneFrontier Corporation. The expanded collaboration now also covers the generation of HuCAL-derived fully human antibodies for proteome research and target validation together with a renowned Japanese research organization as well as commercialization of resulting antibody products. Under the terms of the agreement, GeneFrontier will utilize MorphoSys's HuCAL GOLD antibody library to generate novel HuCAL antibodies against targets provided by its collaboration partner. For this purpose, the HuCAL antibody technology was installed at GeneFrontier's research laboratories within a research facility in Tokyo. GeneFrontier will provide MorphoSys with financial compensation for access to the HuCAL technology. GeneFrontier and MorphoSys agreed to share commercialization rights for all antibodies discovered in this project against targets identified and validated by GeneFrontier with its partner. Further financial details of the agreement were not disclosed.